ReviewDiagnostics (Basel, Switzerland)2021
Diagnostic Strategies for Treatment Selection in Advanced Prostate Cancer.
Review in Diagnostics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Effectiveness and Safety of Prostatic Artery Embolization for Patients with Prostate Cancer: A Systematic Review and Meta-Analysis.Cardiovascular and interventional radiology · 2025Pooled it
- Systematic Biopsy vs. Prostatectomy: Evaluating Correlations and Grading Discrepancies in Prostate Cancer.Cureus · 2024Article
- Addressing controversial areas in the management of advanced prostate cancer in Canada Areas of consensus and controversy from the third Canadian consensus forum.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2024Article
- Amphibian-Derived Natural Anticancer Peptides and Proteins: Mechanism of Action, Application Strategies, and Prospects.International journal of molecular sciences · 2023Review
- Identification of characteristic metabolic panels for different stages of prostate cancer byJournal of translational medicine · 2022Article
- Comprehensive Analysis of m5C Methylation Regulatory Genes and Tumor Microenvironment in Prostate Cancer.Frontiers in immunology · 2022Article
- Glucose-Functionalized Silver Nanoparticles as a Potential New Therapy Agent Targeting Hormone-Resistant Prostate Cancer cells.International journal of nanomedicine · 2022Article
- PathogenicCancers · 2021Review
- Antitumor Activity and Mechanism of Action of Hormonotoxin, an LHRH Analog Conjugated to Dermaseptin-B2, a Multifunctional Antimicrobial Peptide.International journal of molecular sciences · 2021Article
- AR-V7 in Metastatic Prostate Cancer: A Strategy beyond Redemption.International journal of molecular sciences · 2021Review
- BRCA Germline Mutations in Prostate Cancer: The Future Is Tailored.Diagnostics (Basel, Switzerland) · 2021Article
- RNA m6A Methylation Regulators Multi-Omics Analysis in Prostate Cancer.Frontiers in genetics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate Cancer (PCa) is a leading cause of morbidity and mortality among men worldwide. For most men with PCa, their disease will follow an indolent course. However, advanced PCa is associated with poor outcomes. There has been an advent of new therapeutic options with proven efficacy for advanced PCa in the last decade which has improved survival outcomes for men with this disease. Despite this, advanced PCa continues to be associated with a high rate of death. There is a lack of strong evidence guiding the timing and sequence of these novel treatment strategies. This paper focuses on a review of the strategies for diagnostic and the current evidence available for treatment selection in advanced PCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.